Sort   by:  
 Page size 
MetabolomicsAdjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a Phase IIA open-label pilot clinical trial

Drug-resistant tuberculosis (TB) remains a major global health challenge. Host-directed therapies (HDTs) aim to limit tissue damage, shorten treatment, and improve outcomes by modulating immune responses. We evaluated the safety and potential efficacy of adjunctive ibuprofen an inexpens...

2026-05-28 | MTBLS13376 | MetaboLights
MetabolomicsWhole genome CRISPRi screening identifies druggable vulnerabilities in drug-resistant Mycobacterium tuberculosis

Tuberculosis (TB) remains a global health threat, aggravated by the emergence of drug-resistant strains. This study aims to identify genes and metabolic pathways with increased vulnerability in drug-resistant Mycobacterium tuberculosis strains compared to their drug-susceptible counterparts. Usin...

2024-10-15 | MTBLS11277 | MetaboLights
MetabolomicsL-leucine increases the sensitivity of drug-resistant Salmonella to sarafloxacin by stimulating central carbon metabolism and increasing intracellular reactive oxygen species level (LC-MS positive mode)

The overuse of antibiotics has made public health and safety face a serious crisis. It is urgent to develop new clinical treatment methods to combat drug-resistant bacteria to alleviate the health crisis. The efficiency of antibiotics is closely related to the metabolic state of bacteria. However...

2023-05-02 | MTBLS7711 | MetaboLights
MetabolomicsL-leucine increases the sensitivity of drug-resistant Salmonella to sarafloxacin by stimulating central carbon metabolism and increasing intracellular reactive oxygen species level (LC-MS negative mode)

The overuse of antibiotics has made public health and safety face a serious crisis. It is urgent to develop new clinical treatment methods to combat drug-resistant bacteria to alleviate the health crisis. The efficiency of antibiotics is closely related to the metabolic state of bacteria. However...

2023-05-02 | MTBLS7713 | MetaboLights
MetabolomicsValine potentiates cefoperazone-sulbactam to kill methicillin resistant Staphylococcus aureus

Metabolic state-reprogramming approach was extended from Gram-negative bacteria to Gram-positive bacterium methicillin-resistant Staphylococcus aureus (MRSA) for identifying desired reprogramming metabolites to synergize existing antibiotic killing to MRSA. Metabolomics comparison between MRSA an...

2024-12-12 | MTBLS11540 | MetaboLights
MetabolomicsExogenous L-Alanine promotes phagocytosis multidrug-resistant bacterial pathogens (V. parahaemolyticus-infected spleen metabolomics)

Multidrug-resistant bacteria present a major threat to public health. Therefore, new drugs or approaches are urgently needed to manage and mitigate this threat. Here, we screen the molecular candidates that allow the survival of mice upon Vibrio parahaemolyticus infection by integrated p...

2024-09-26 | MTBLS7996 | MetaboLights
Metabolomics1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
1H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1]6+ as potential anticancer drug. Human ovarian cancer cell...
2015-01-16 | MTBLS156 | MetaboLights
MetabolomicsPiperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages.
Not available
ORGANISM(S): Plasmodium falciparum 
ST002181 | MetabolomicsWorkbench
MetabolomicsUntargeted 1 H NMR-based metabolomics unveils distinct circulating biochemical signatures between treatment-resistant and non-treatment-resistant Schizophrenia patients: a pilot study

Schizophrenia is a severe psychiatric disorder impacting roughly 1% of individuals. The effectiveness of antipsychotic therapy greatly varies, with around 30% of patients categorised as treatment-resistant (TRS). TRS is characterised by a lack of response to at least two clinical trials invo...

2025-10-01 | MTBLS12709 | MetaboLights
MetabolomicsUntargeted metabolomics to understand the basis of phenotypic differences in amphotericin B-resistant Leishmania parasites

BACKGROUND: Protozoan Leishmania parasites are responsible for a range of clinical infections that represent a substantial challenge for global health. Amphotericin B (AmB) is increasingly used to treat Leishmania infection, so understanding the potential for resistance to this d...

2019-09-26 | MTBLS1167 | MetaboLights
Sort   by:  
 Page size